Evidence map›Paper›PMID 26582908›Full record

ArticleStem cells translational medicine2016

Magnetic Resonance Imaging of Iron Oxide-Labeled Human Embryonic Stem Cell-Derived Cardiac Progenitors.

Rhys J P Skelton, Suhail Khoja, Shone Almeida, Stanislas Rapacchi, Fei Han, James Engel, Peng Zhao, Peng Hu, Edouard G Stanley, Andrew G Elefanty and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Rhys J P SkeltonDivision of Cardiology, Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA Murdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, California, USA.
Suhail KhojaEli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, California, USA.
Shone AlmeidaDivision of Cardiology, Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Stanislas RapacchiDivision of Radiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Fei HanDivision of Radiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
James EngelEli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, California, USA.
Peng ZhaoEli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, California, USA.
Peng HuDivision of Radiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Edouard G StanleyMurdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.
Andrew G ElefantyMurdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.
Murray KwonDivision of Cardiothoracic Surgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
David A ElliottMurdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia RArdehali@mednet.ucla.edu david.elliott@mcri.edu.au.
Reza ArdehaliDivision of Cardiology, Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, California, USA RArdehali@mednet.ucla.edu david.elliott@mcri.edu.au.
University of California, Los Angeles · USRoyal Children's Hospital · AU

Funding

Training in Molecular, Cellular &Integrative PhysiologyT32GM065823 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIDBALL, JAMES G · 2003 to 2017
$2.1M
NIGMS NIH HHS T32 GM065823
6 · The paper itself

Abstract

unlabelledGiven the limited regenerative capacity of the heart, cellular therapy with stem cell-derived cardiac cells could be a potential treatment for patients with heart disease. However, reliable imaging techniques to longitudinally assess engraftment of the transplanted cells are scant. To address this issue, we used ferumoxytol as a labeling agent of human embryonic stem cell-derived cardiac progenitor cells (hESC-CPCs) to facilitate tracking by magnetic resonance imaging (MRI) in a large animal model. Differentiating hESCs were exposed to ferumoxytol at different time points and varying concentrations. We determined that treatment with ferumoxytol at 300 μg/ml on day 0 of cardiac differentiation offered adequate cell viability and signal intensity for MRI detection without compromising further differentiation into definitive cardiac lineages. Labeled hESC-CPCs were transplanted by open surgical methods into the left ventricular free wall of uninjured pig hearts and imaged both ex vivo and in vivo. Comprehensive T2*-weighted images were obtained immediately after transplantation and 40 days later before termination. The localization and dispersion of labeled cells could be effectively imaged and tracked at days 0 and 40 by MRI. Thus, under the described conditions, ferumoxytol can be used as a long-term, differentiation-neutral cell-labeling agent to track transplanted hESC-CPCs in vivo using MRI. SIGNIFICANCE: The development of a safe and reproducible in vivo imaging technique to track the fate of transplanted human embryonic stem cell-derived cardiac progenitor cells (hESC-CPCs) is a necessary step to clinical translation. An iron oxide nanoparticle (ferumoxytol)-based approach was used for cell labeling and subsequent in vivo magnetic resonance imaging monitoring of hESC-CPCs transplanted into uninjured pig hearts. The present results demonstrate the use of ferumoxytol labeling and imaging techniques in tracking the location and dispersion of cell grafts, highlighting its utility in future cardiac stem cell therapy trials.

Indexed as

Embryonic Stem CellsMagnetic Resonance ImagingMyoblasts, CardiacStem Cell TransplantationCell TrackingFerric CompoundsFerrosoferric OxideHeterograftsHumansRadiographyFerric Compoundsferric oxideFerrosoferric OxideCardiac stem cell biologyCardiovascular progenitorsCell labelingMagnetic resonance imagingStem cell therapy

Identifiers

PMID26582908
PMCPMC4704872
OpenAlexW2180312538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.